Where does Veronica Gambillara Fonck work?

Veronica Gambillara Fonck is Partner at Pureos Bioventures.

What check size does Veronica Gambillara Fonck write?

Veronica Gambillara Fonck typically writes checks of $100K – $5M.

What companies has Veronica Gambillara Fonck invested in?

Investments tracked here include AnaCardio, Memo Therapeutics, MinervaX.

Where did Veronica Gambillara Fonck go to school?

Veronica Gambillara Fonck studied at IMD (High Performance Boards Program); IMD (Master of Business Administration - MBA, Finance); The MBA training Company (3 days MBA in Pharmaceuticals).

Veronica Gambillara Fonck

Investor

Partner at Pureos Bioventures

Zurich, Switzerland

Writes $100K – $5M checks · typically $1.5M

Find your path to Veronica

289 people in our graph share verified history with Veronica — schools, employers, funds. One of them is your warm intro.

Michael ZehnderunlockedVeronica: together at IMD (2017–2018)

×3Veronica: together at Allergan

×4Veronica: together at IMD

Veronica: together at MinervaX

About

Veronica Gambillara Fonck is a partner at Pureos Bioventures and serves as Chairperson of the Board at Minervax ApS. She brings experience in corporate and product development strategy, clinical and regulatory matters in biotech and medtech, and international operations across multiple language markets.

Contact· self-published, not guessed

v•••@pureosbio.comreveal

Experience

Minervax ApSChairperson of the Boardcurrent2024 — presentCopenhagen, Capital Region of Denmark, Denmark
Pureos BioventuresPartnercurrent2022 — presentZurich, Switzerland
GlycoEra AGCEO-and Co-Founder2021 — 2022Zurich, Switzerland
LimmaTech Biologics AGCEO-Co-founder2015 — 2021Schlieren, Kanton Zürich, Switzerland
Glycovaxyn AGExecutive Director, Clinical and Regulatory Affairs2012 — 2015Zurich
Glycovaxyn AGDirector Business Development2011 — 2012Zurich
Glycovaxyn AGDirector Clinical and Regulatory Affairs2009 — 2011
AllerganManager Clinical Affairs2007 — 2009
EndoArt SAProject Manager2006 — 2007
Ecole Polytechnique de LausanneResearch Assistant2001 — 2005

Skills & more

Business Development10Clinical Affairs7Regulatory Affairs12Regulatory Submissions10Clinical Trials19Clinical Development16Clinical Research11Vaccines7Immunology6Biochemistry3Biomedical Engineering3Molecular Biology4

+12 more

LifesciencesMedical DevicesPharmaceutical IndustryProject ManagementBiotechnologyBusiness StrategyInfectious DiseasesR&DLife SciencesManagementLeadershipStrategy

Languages English · French · German · Italian

From Veronica's professional profile.

Investments

Investor

AnaCardio Memo Therapeutics MinervaX

Per curated public sources.

Colleagues at Pureos Bioventures

Anne Grahl

Associate at Pureos Bioventures

Butrint Aliu

Analyst at Pureos Bioventures

Christian Altorfer

CFO/COO at Pureos Bioventures

Dominik Escher

Managing Partner at Pureos Bioventures

Dragan Grabulovski

Venture Partner at Pureos Bioventures

Klaus Breiner

Managing Partner at Pureos Bioventures

Lars Nieba

Venture Partner at Pureos Bioventures

Martin Münchbach

Managing Partner at Pureos Bioventures

Frequently asked questions

Who is Veronica Gambillara Fonck?: Veronica Gambillara Fonck is a partner at Pureos Bioventures and serves as Chairperson of the Board at Minervax ApS. She brings experience in corporate and product development strategy, clinical and regulatory matters in biotech and medtech, and international operations across multiple language markets.
Where does Veronica Gambillara Fonck work?: Veronica Gambillara Fonck is Partner at Pureos Bioventures.
What check size does Veronica Gambillara Fonck write?: Veronica Gambillara Fonck typically writes checks of $100K – $5M.
What companies has Veronica Gambillara Fonck invested in?: Investments tracked here include AnaCardio, Memo Therapeutics, MinervaX.
Where did Veronica Gambillara Fonck go to school?: Veronica Gambillara Fonck studied at IMD (High Performance Boards Program); IMD (Master of Business Administration - MBA, Finance); The MBA training Company (3 days MBA in Pharmaceuticals).